Literature DB >> 33479353

Network analysis of Down syndrome and SARS-CoV-2 identifies risk and protective factors for COVID-19.

Ilario De Toma1, Mara Dierssen2,3,4.   

Abstract

SARS-CoV-2 infection has spread uncontrollably worldwide while it remains unknown how vulnerable populations, such as Down syndrome (DS) individuals are affected by the COVID-19 pandemic. Individuals with DS have more risk of infections with respiratory complications and present signs of auto-inflammation. They also present with multiple comorbidities that are associated with poorer COVID-19 prognosis in the general population. All this might place DS individuals at higher risk of SARS-CoV-2 infection or poorer clinical outcomes. In order to get insight into the interplay between DS genes and SARS-cov2 infection and pathogenesis we identified the genes associated with the molecular pathways involved in COVID-19 and the host proteins interacting with viral proteins from SARS-CoV-2. We then analyzed the overlaps of these genes with HSA21 genes, HSA21 interactors and other genes consistently differentially expressed in DS (using public transcriptomic datasets) and created a DS-SARS-CoV-2 network. We detected COVID-19 protective and risk factors among HSA21 genes and interactors and/or DS deregulated genes that might affect the susceptibility of individuals with DS both at the infection stage and in the progression to acute respiratory distress syndrome. Our analysis suggests that at the infection stage DS individuals might be more susceptible to infection due to triplication of TMPRSS2, that primes the viral S protein for entry in the host cells. However, as the anti-viral interferon I signaling is also upregulated in DS, this might increase the initial anti-viral response, inhibiting viral genome release, viral replication and viral assembly. In the second pro-inflammatory immunopathogenic phase of the infection, the prognosis for DS patients might worsen due to upregulation of inflammatory genes that might favor the typical cytokine storm of COVID-19. We also detected strong downregulation of the NLRP3 gene, critical for maintenance of homeostasis against pathogenic infections, possibly leading to bacterial infection complications.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33479353      PMCID: PMC7820501          DOI: 10.1038/s41598-021-81451-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  79 in total

1.  Intrinsic abnormalities of lymphocyte counts in children with down syndrome.

Authors:  Yvette C M de Hingh; Petrus W van der Vossen; Eugenie F A Gemen; André B Mulder; Wim C J Hop; Frank Brus; Esther de Vries
Journal:  J Pediatr       Date:  2005-12       Impact factor: 4.406

2.  BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis.

Authors:  Steffen Durinck; Yves Moreau; Arek Kasprzyk; Sean Davis; Bart De Moor; Alvis Brazma; Wolfgang Huber
Journal:  Bioinformatics       Date:  2005-08-15       Impact factor: 6.937

3.  Functionality of the pneumococcal antibody response in Down syndrome subjects.

Authors:  M A A Kusters; N C C Manders; B A W de Jong; R W N M van Hout; G T Rijkers; E de Vries
Journal:  Vaccine       Date:  2013-11-05       Impact factor: 3.641

4.  Dynamic induction of ADAMTS1 gene in the early phase of acute myocardial infarction.

Authors:  Keigo Nakamura; Satoshi Hirohata; Takashi Murakami; Toru Miyoshi; Kadir Demircan; Toshitaka Oohashi; Hiroko Ogawa; Kazuya Koten; Kenichi Toeda; Shozo Kusachi; Yoshifumi Ninomiya; Yasushi Shiratori
Journal:  J Biochem       Date:  2004-10       Impact factor: 3.387

5.  The App-Runx1 region is critical for birth defects and electrocardiographic dysfunctions observed in a Down syndrome mouse model.

Authors:  Matthieu Raveau; Jacques M Lignon; Valérie Nalesso; Arnaud Duchon; Yoram Groner; Andrew J Sharp; Doulaye Dembele; Véronique Brault; Yann Hérault
Journal:  PLoS Genet       Date:  2012-05-31       Impact factor: 5.917

6.  Gene expression profiling in a mouse model identifies fetal liver- and placenta-derived potential biomarkers for Down Syndrome screening.

Authors:  Jeroen L A Pennings; Wendy Rodenburg; Sandra Imholz; Maria P H Koster; Conny T M van Oostrom; Timo M Breit; Peter C J I Schielen; Annemieke de Vries
Journal:  PLoS One       Date:  2011-04-14       Impact factor: 3.240

7.  Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 Overexpression.

Authors:  Cody T Mowery; Jaime M Reyes; Lucia Cabal-Hierro; Kelly J Higby; Kristen L Karlin; Jarey H Wang; Robert J Kimmerling; Paloma Cejas; Klothilda Lim; Hubo Li; Takashi Furusawa; Henry W Long; David Pellman; Bjoern Chapuy; Michael Bustin; Scott R Manalis; Thomas F Westbrook; Charles Y Lin; Andrew A Lane
Journal:  Cell Rep       Date:  2018-11-13       Impact factor: 9.423

8.  Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21.

Authors:  Youssef Hibaoui; Iwona Grad; Audrey Letourneau; M Reza Sailani; Sophie Dahoun; Federico A Santoni; Stefania Gimelli; Michel Guipponi; Marie Francoise Pelte; Frédérique Béna; Stylianos E Antonarakis; Anis Feki
Journal:  EMBO Mol Med       Date:  2013-12-27       Impact factor: 12.137

9.  Virus-Host Interactome and Proteomic Survey Reveal Potential Virulence Factors Influencing SARS-CoV-2 Pathogenesis.

Authors:  Jingjiao Li; Mingquan Guo; Xiaoxu Tian; Xin Wang; Xing Yang; Ping Wu; Chengrong Liu; Zixuan Xiao; Yafei Qu; Yue Yin; Chunxia Wang; Yucai Zhang; Zhaoqin Zhu; Zhenshan Liu; Chao Peng; Tongyu Zhu; Qiming Liang
Journal:  Med (N Y)       Date:  2020-07-21

Review 10.  Inhibition of the OAS/RNase L pathway by viruses.

Authors:  Melissa Drappier; Thomas Michiels
Journal:  Curr Opin Virol       Date:  2015-07-29       Impact factor: 7.090

View more
  17 in total

1.  Comparison of COVID-19 and Non-COVID-19 Pneumonia in Down Syndrome.

Authors:  Diego Real de Asua; Miguel A Mayer; María Del Carmen Ortega; Jose M Borrel; Teresa de Jesús Bermejo; Domingo González-Lamuño; Coral Manso; Fernando Moldenhauer; María Carmona-Iragui; Anke Hüls; Stephanie L Sherman; Andre Strydom; Rafael de la Torre; Mara Dierssen
Journal:  J Clin Med       Date:  2021-08-23       Impact factor: 4.241

2.  COVID-19 and Down syndrome: the spark in the fuel.

Authors:  Manini Majithia; Susan P Ribeiro
Journal:  Nat Rev Immunol       Date:  2022-07       Impact factor: 108.555

3.  Clinical characteristics and comorbidities of COVID-19 in unvaccinated patients with Down syndrome: first year report in Brazil.

Authors:  Matheus Negri Boschiero; Camila Vantini Capasso Palamim; Fernando Augusto Lima Marson; Manoela Marques Ortega
Journal:  Hum Genet       Date:  2022-06-28       Impact factor: 5.881

Review 4.  Beyond amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer disease in people with Down syndrome.

Authors:  Alessandra C Martini; Thomas J Gross; Elizabeth Head; Mark Mapstone
Journal:  Neuron       Date:  2022-04-25       Impact factor: 18.688

5.  Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey.

Authors:  Anke Hüls; Alberto C S Costa; Mara Dierssen; R Asaad Baksh; Stefania Bargagna; Nicole T Baumer; Ana Claudia Brandão; Angelo Carfi; Maria Carmona-Iragui; Brian Allen Chicoine; Sujay Ghosh; Monica Lakhanpaul; Coral Manso; Miguel-Angel Mayer; Maria Del Carmen Ortega; Diego Real de Asua; Anne-Sophie Rebillat; Lauren Ashley Russell; Giuseppina Sgandurra; Diletta Valentini; Stephanie L Sherman; Andre Strydom
Journal:  EClinicalMedicine       Date:  2021-02-22

6.  COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey.

Authors:  David Emes; Anke Hüls; Nicole Baumer; Mara Dierssen; Shiela Puri; Lauren Russell; Stephanie L Sherman; Andre Strydom; Stefania Bargagna; Ana Cláudia Brandão; Alberto C S Costa; Patrick T Feany; Brian Allen Chicoine; Sujay Ghosh; Anne-Sophie Rebillat; Giuseppina Sgandurra; Diletta Valentini; Tilman R Rohrer; Johannes Levin; Monica Lakhanpaul
Journal:  J Clin Med       Date:  2021-10-31       Impact factor: 4.241

7.  Multiple Organ Failure Associated with SARS-CoV-2 Infection in a Child with Down Syndrome: Is Trisomy 21 Associated with an Unfavourable Clinical Course?

Authors:  Perla Idalia Vazquez-Hernández; Alan Cárdenas-Conejo; Manuel Alejandro Catalán-Ruiz; Karla Navar-Gallegos; Emilio Zenteno-Salazar; Jose Rafael-Parra-Bravo; Ranferi Aragon-Nogales; Maribel Ibarra-Sarlat; Juan Carlos Núñez-Enríquez
Journal:  Case Rep Pediatr       Date:  2021-11-01

8.  ORF8 and Health Complications of COVID-19 in Down Syndrome Patients.

Authors:  Antonio Bensussen; Antonio Valcarcel; Elena R Álvarez-Buylla; José Díaz
Journal:  Front Genet       Date:  2022-02-09       Impact factor: 4.599

9.  Differential microRNA expression profile in blood of children with Down syndrome suggests a role in immunological dysfunction.

Authors:  Joice Matos Biselli; Bruna Lancia Zampieri; Patrícia Matos Biselli-Chicote; Jorge Estefano Santana de Souza; Matheus Carvalho Bürger; Wilson Araújo da Silva; Eny Maria Goloni-Bertollo; Érika Cristina Pavarino
Journal:  Hum Cell       Date:  2022-01-20       Impact factor: 4.374

10.  Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome.

Authors:  Xu-Qiao Chen; Zhuo Xing; Quang-Di Chen; Richard J Salvi; Xuming Zhang; Benjamin Tycko; William C Mobley; Y Eugene Yu
Journal:  Front Aging Neurosci       Date:  2021-07-01       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.